statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
KALA stock results show that Kala Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023.
The post...

KALA Stock Earnings: Kala Pharmaceuticals Beats EPS for Q4 2023

Kala Pharmaceuticals GAAP EPS of -$3.18 beats by $0.44...

Kala Pharmaceuticals GAAP EPS of -$3.18 beats by $0.44

-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 ---- Exploring opportunities to expand KPI-012 into additional corneal indications ---- Cash...

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

ARLINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...

KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

ARLINGTON, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...

KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

ARLINGTON, Mass., Jan. 19, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award...

KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KALA BIO, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.

Watchers	8,863
52-Wk Low	$5.10
52-Wk High	$16.83

Volume	8,469.00
52-Wk High	$16.83
52-Wk Low	$5.10

Current Price	$6.57
Prev Close	$6.83
Open	$6.73
Dividend Yield	0.00%
50-Day Moving Average	$6.91
Beta	1.27
Avg. Volume	26,835.00
PE Ratio	-0.43

52-Week High	$16.83
52-Week Low	$5.10
Market Capitalization	$18.5M
EPS	-$15.15
Price to Book	2.78
Revenue Per Employee	N/A
Enterprise Value/EBITDA	-0.26

KALA Kala Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals